New hope for Tough-to-Treat lung cancer: trial tests Triple-Threat therapy
NCT ID NCT05937906
Summary
This study is testing a new combination of drugs for people with a specific type of advanced lung cancer that has spread. The goal is to see if adding a short course of a drug called mirdametinib to standard chemotherapy and immunotherapy is safe and more effective at controlling the cancer. The trial will first find the best dose and then test that dose in more patients.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Centre Georges-François Leclerc
RECRUITINGDijon, Burgundy, 21000, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.